All News
Filter News
Found 806,088 articles
-
Double Black Imaging Brings LG's Cutting-Edge Display Systems to Radiology Imaging Markets
5/13/2020
Double Black Imaging (DBI) today announced the immediate availability of two radiology-focused medical-grade displays from LG Electronics bundled with DBI's comprehensive calibration software package.
-
PulsePoint Launches Turnkey NPI Targeting And Reporting With HCP Direct Match™
5/13/2020
PulsePoint, a technology company using real-time data to accelerate health marketing, today announced the launch of HCP Direct Match™, the industry's first turnkey people-based targeting solution.
-
Equillium Reports First Quarter 2020 Financial Results
5/13/2020
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2020.
-
Aleafia Health Announces $6.4M Positive Adjusted EBITDA, $14.6M Net Revenue in Q1 2020
5/13/2020
Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), is pleased to report its financial results for the three months ended March 31, 2020 (“Q1 2020”).
-
ProMIS Neurosciences Announces First Quarter 2020 Results
5/13/2020
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2020. “Over the course of the first quarter 2020, the value of our unique discovery a
-
Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020
5/13/2020
Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Pre
-
CTI Invents Thermochromic Inks Free of Bisphenol A, F and S in Response to Pharmaceutical Demand
5/13/2020
As the world's supply chain for pharmaceutical drugs comes under increasing scrutiny for safety and quality, Chromatic Technologies Inc. (CTI) has introduced printable thermochromic technology that is free of Bisphenol A, F and S.
-
GO2 Foundation for Lung Cancer Names Jennifer C. King, Ph.D. as Chief Scientific Officer
5/13/2020
GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer.
-
Pennant Reports Fiscal Year 2020 First Quarter Financial ResultsConference Call and Webcast scheduled for tomorrow, May 14, 2020 at 10:00 am MT
5/13/2020
The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results for the first quarter of fiscal year 2020, reporting GAAP diluted earnings per share of $0.10 for the quarter and adjusted diluted earnings per share of $0.16 for the quarter(1).
-
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
5/13/2020
Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform therapy called Tumor Treating Fields, and Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for Optune in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma
-
XLerateHealth and the Southeast XLerator Network Announce National Institutes of Health Funding for Seven Novel Healthcare Research Projects
5/13/2020
XLerateHealth (XLH), its affiliate, the Southeast XLerator Network (XLN), and XLN Academic Lead, the University of Kentucky, are pleased to announce that the National Institutes of Health (NIH) has approved XLN’s External Advisory Committee’s (EAC) recommendation to fund the continued development of seven biomedical innovations that represent various areas of technology, from medical devices to diagnostics and therapeutics.
-
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020
5/13/2020
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date - - Company to host conference call and webcast today at 8:00am ET - GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated vi
-
Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders
5/13/2020
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of Stockholders
-
RDIF and ChemRar Announce First Interim Results of Clinical Trials of Favipiravir Drug's Effectiveness in Coronavirus Therapy
5/13/2020
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and the ChemRar Group today announce the positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19.
-
Happiness Biotech Announced Innovative Cultivation Technology of Lucidum
5/13/2020
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company has successfully developed an innovative cultivation technology of lucidum, which enables the Company to reduce the cost of growing lucidum - one of the main raw materials of the Company's products, by over 30%.
-
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
5/13/2020
Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced positive interim Phase 1b data from a study with VIB7734, its novel anti-ILT7 therapy, in patients with cutaneous lupus erythematosus (CLE).
-
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
5/13/2020
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020 , it has reached agreement with the FDA to resubmit its application for HETLIOZ® (tasimelteon) for the treatment of Smith-Magenis Syndrome (SMS). As previously
-
QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)
5/13/2020
QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a $42 million Series A financing, bringing the total funds raised to $50.5 million.
-
Pharmaceutical Executive® Announces Winners of the 2020 Emerging Pharma Leaders Awards
5/13/2020
Pharmaceutical Executive®, a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, is proud to announce the honorees of the 2020 Emerging Pharma Leaders awards program
-
Viela Bio Reports First Quarter 2020 Financial Results and Program HighlightsCompany to host investor conference call and webcast today at 5:00 pm ET
5/13/2020
Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and provided program highlights for the first quarter ended March 31, 2020.